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To the Editor:
We read with great interest the study by Fang and
colleagues [1] that evaluated the association of HBV
core promoter double mutations (A1762T and
G1764A) with viral loads between HBeAg positive and
anti-HBe positive individuals. In their study, the authors
concluded that BCP double mutations are associated
with lower viral loads in HBeAg positive individuals,
but have no eﬀect on the viral loads of anti-HBe positive
individuals. Our concerns regarding this study and its
conclusions are outlined as follows:
It is well known that treatment with an antiviral
therapy, such as lamivudine therapy, can give rise
to HBV mutations, including core promoter muta-
tions [2] or biochemical and virological breakthrough
[3]. Moreover, antiviral therapies, including nucleotide
analogy, are widely used for the treatment of hepatitis
B in urban and rural areas of China. Although the
authors have mentioned that no subject received anti-
viral or immunosuppressive therapy during the 3-year
follow-up period, the authors still have not stated
whether the subjects enrolled in the present study
had been treated with any antiviral therapy in the
early days prior to their inclusion in the study. In
other words, if some subjects enrolled in this study
had received antiviral therapy prior to the study,
which could have inﬂuenced the results. Therefore,
it is important to further address the above-men-
tioned question in the context of the study.
The eﬀect of BCP double mutations on viral loads re-
mains uncertain [1,4,5]. In this study, cross-sectional anal-
ysis and longitudinal analysis have been utilized for
evaluating the association of HBV core promoter double
mutations (A1762T and G1764A) with viral loads, and
more reliable results have been obtained by the authors
[1]. However, viral replication, as measured by viral loads
in vivo, is inﬂuenced by the interaction of the viruswith the
host immune system, and this has been admitted by the
authors and colleagues [1] and ascertained by Chu and
colleagues [6]. That is to say, when we are attempting to
investigate viral loads, we should also be paying attention
to the inﬂuence of the viral and host factors, such as age,
sex and viral genotype, etc., on viral loads. In Table 3 [1],
however, the authors have not provided any details
regarding the baseline characteristics of subjects, includ-
ing age, sex and viral genotype, either for the BCP double
mutation subgroup or for the wild-type subgroup. More-
over, it is also unclear whether viral loads were associated
with the other factors considered, including age, sex and
viral genotype, either in the BCP double mutations sub-
group or in the wild-type subgroup. Therefore, the afore-
mentioned question needs to be considered and further
investigated.
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The association of HBV core promoter double mutations (A1762T
and G1764A) with viral load diﬀers between HBeAg positive
and anti-HBe positive individuals: A longitudinal analysis – Reply
To the Editor:
Pan et al. [1] have expressed two concerns regarding
our study. First, although no study subjects received
antiviral therapy during the period of follow-up, some
individuals may have been treated prior to the study.
The members of the Long An cohort are low-income
agricultural workers unlikely to be able to aﬀord antivi-
ral drugs, and none reported their use when questioned
speciﬁcally at recruitment. Even if a few individuals had
received therapy previously, their viral loads should
have rebounded after the end of treatment and the lon-
gitudinal analysis carried out ensured that our results
would not have been inﬂuenced. Furthermore, the
diﬀerential eﬀects of BCP mutations on viral load in
HBeAg-positive and in HBeAg-negative patients have
been reported by other investigators [2]. The strength
of our study lies in the longitudinal analysis.
Their second point is that other factors, such as age,
sex and viral genotype, may have inﬂuenced the viral
loads. As stated in the methods Section 2.7.1 ‘Cross-sec-
tional analysis’, multiple linear regression analysis was
used to assess whether any diﬀerences detected remained
signiﬁcant after adjusting for HBeAg status and those
speciﬁc factors [3]. That was the case, although, for rea-
sons of brevity, those analyses were not detailed in the
paper. We do not consider that either of these issues
compromises our ﬁndings.
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The retroviral myth of primary biliary cirrhosis:
Is this (ﬁnally) the end of the story?
To the Editor:
The retroviral story of primary biliary cirrhosis
(PBC) has been enriched by a new episode in the
March issue of this Journal. In their article, Johal
and colleagues report their study of a large number
of liver samples taken from patients aﬀected by
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